MINI REVIEW article
Front. Oncol.
Sec. Surgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1621862
This article is part of the Research TopicAdvances in Esophageal Cancer: Treatment Updates and Future ChallengesView all 13 articles
Evolution of Lymph Node Staging in Esophageal Squamous Cell Carcinoma: Insights from Lymph Node Metastatic Stations
Provisionally accepted
- 1Sichuan Cancer Hospital, Chengdu, China
- 2Yunnan cancer hospital, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Esophageal squamous cell carcinoma (ESCC) is a globally prevalent malignancy with distinct regional variations, particularly concentrated in East Asia, including China and Japan.The Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) system offers simplicity but lacks emphasis on anatomical specificity, such as upper mediastinal metastases. Conversely, the Japan Esophageal Society (JES) system provides detailed regional stratification, aiding preoperative planning and tailored therapy, though it demands greater clinical expertise. This review evaluates the current state of pathological lymph node staging systems for ESCC, comparing the UICC/AJCC and JES approaches and exploring emerging trends in China toward station-based staging.
Keywords: esophageal squamous cell carcinoma, Pathological N-Category, Lymph Node, prognosis, UICC/AJCC, JES
Received: 02 May 2025; Accepted: 03 Jul 2025.
Copyright: © 2025 Li, Lu, Mao, Han, Peng and Leng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kexun Li, Sichuan Cancer Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.